

IN THE CLAIMS

1. (Previously presented) A method of treating inflammatory bowel disease (IBD) in a patient in need thereof which comprises orally administering to the patient an effective amount of a pooled human polyclonal immunoglobulin preparation.

2. (Original) The method according to Claim 1 wherein the inflammatory bowel disease is ulcerative colitis (UC).

3. (Original) The method according to Claim 1 wherein the inflammatory bowel disease is Crohn's disease.

4. (Previously presented) A method of treating mucosal inflammation which comprises orally administering to a patient suffering from said mucosal inflammation an effective amount of a pooled human polyclonal immunoglobulin preparation.

5. (Original) The method according to any one of Claims 1-4 wherein the immunoglobulin is at least one of immunoglobulin G (IgG), immunoglobulin A (IgA) or a mixture of immunoglobulin G (IgG) and immunoglobulin A (IgA).

6. (Original) The method according to any one of Claims 1-4 wherein the immunoglobulin preparation is dispersed in a pharmaceutically acceptable carrier.

7. (Original) The method according to any one of Claims 1-4 wherein the amount of immunoglobulin administered to said patient is from about 0.5 to 1.5 grams at least once a day.

8. (Original) The method according to any one of Claims 1-4 wherein the immunoglobulin is enterically coated.

9. (Previously presented) A method of treating inflammatory bowel disease (IBD) in a patient in need thereof which comprises orally administering to the patient a pooled human polyclonal immunoglobulin preparation comprising at least about 25% IgG antibodies.

10. (Previously presented) A method of treating mucosal inflammation which comprises orally administering to a patient suffering from said mucosal inflammation a pooled human polyclonal immunoglobulin preparation comprising at least about 25% IgG antibodies.

11-15. (Cancelled)